Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

This study uses advanced imaging (MRI and other scans) taken before and during chemotherapy plus immunotherapy to try to predict which patients with triple-negative breast cancer (TNBC) will have a complete response to treatment before surgery. The goal is to develop imaging tools that help doctors personalize treatment plans without waiting for surgery results. **You may be eligible if:** - You have a confirmed diagnosis of triple-negative breast cancer (TNBC) by biopsy - You are planning to receive neoadjuvant (pre-surgery) chemotherapy plus immunotherapy - You are between 18 and 75 years old - You are covered by or eligible for social health protection **You may NOT be eligible if:** - You are pregnant or breastfeeding - You have a contraindication to the planned treatment - You do not have confirmed TNBC - You are outside the eligible age range Talk to your doctor to see if this trial is right for you.